The UAB CFAR has operated a Central Virus Core (CVC) shared resources since 1988.
The specific aims of this core are: (i) To provide specially-designed, centrally-located BSL-2/3 laboratory space to all UAB investigators so that infectious HIV research can be physically restricted to specific areas; (ii) To provide high cost equipment needed for basic HIV research on a shared basis within the core facility in order to facilitate and broaden the research capabilities of all investigators and to avoid redundancy in equipment purchases; (iii) To provide ongoing training, supervision, and monitoring of investigators and their research staff regarding BLS-2/3 practices required for HIV research; (iv) To foster the development of HIV/AIDS research by new investigators and to encourage multidisciplinary research by new and established investigators by providing a core staff with broad experience in basic and clinical HIV research which is dedicated to these goals. The CVC consists of two centrally-located biosafety level 2/3 (BSL-2/3) laboratories and their associated professional and technical staff. These laboratories are centrally located on the UAB campus in the vicinity of the greatest concentrations of HIV researchers. Together, they constitute 2500 square feet of BSL-2/3 space including nine self- contained 100 square foot tissue culture suites. Both the individual culture suites and the other common equipment areas are completely equipped for molecular, biological, and clinical HIV research. The core is operated under the specific usage and priority guidelines established by the core's advisory committee and in compliance with NIH/CDC recommendations for safe operating procedures. During the current five year funding period, the CVC has supported federally-funded research projects of 32 UAB faculty representing 10 different departments and divisions within the School of Medicine. The CVC has trained, supervised, and assisted 85 researchers including graduate students, postdoctoral fellows, technicians, and faculty. In addition to R01-type projects, the CVC has supported research for five major NIH funded program projects and contracts awarded to UAB investigators between 1988 and 1993, including NCDDG, NCVDG, PEBRA, ACTG, and HIV Genetic Variation projects. Over 100 peer-reviewed scientific publications have resulted from work performed within the CVC. Funding is requested to support the basic operational costs of the CVC that remain despite a substantial chargeback system already in place.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027767-06
Application #
3747013
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Yang, Zhenhua; Shah, Kushani; Busby, Theodore et al. (2018) Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer. J Clin Invest 128:3605-3618
Stafman, Laura L; Mruthyunjayappa, Smitha; Waters, Alicia M et al. (2018) Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget 9:22665-22679
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Nag, Mukta; De Paris, Kristina; E Fogle, Jonathan (2018) Epigenetic Modulation of CD8? T Cell Function in Lentivirus Infections: A Review. Viruses 10:
Williams, Adele P; Waters, Alicia M; Stewart, Jerry E et al. (2018) A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro. J Surg Res 228:54-62
Holdbrooks, Andrew T; Britain, Colleen M; Bellis, Susan L (2018) ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor. J Biol Chem 293:1610-1622
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Dixit, Saurabh; Sahu, Rajnish; Verma, Richa et al. (2018) Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells. Biomaterials 159:130-145

Showing the most recent 10 out of 955 publications